Clinical Trial Update: Study of 5-Fluorouracil/Leucovorin/Oxaliplatin (FOLFOX) + Bevacizumab Versus 5-Fluorouracil/Leucovorin/Oxaliplatin/Irinotecan (FOLFOXIRI) + Bevacizumab as First Line Treatment of Patients With Metastatic Colorectal Cancer Not Previously Treated and With Three or More Circulating Tumoral Cells [Phase 3]

View source ↗

Summary

Phase 3 trial comparing FOLFOX + Bevacizumab versus FOLFOXIRI + Bevacizumab as first-line treatment for metastatic colorectal cancer; trial completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• 5-Fluorouracil/Leucovorin/Oxaliplatin (FOLFOX)
• Bevacizumab (bevacizumab)
• FOLFOX + Bevacizumab
• FOLFOXIRI + Bevacizumab
• Irinotecan (Irinotecan)

Snippet

Sponsor: Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD) | Conditions: Metastatic Colorectal Cancer | Phase 3 | Status: COMPLETED